Nicole E Rich1, Samuel Phen2, Nirali Desai2, Sukul Mittal2, Adam C Yopp3, Ju Dong Yang4, Jorge A Marrero5, Puneeth Iyengar6, Rodney E Infante7, Amit G Singal5. 1. Division of Digestive and Liver Diseases, Department of Internal Medicine, UT Southwestern, Dallas, Texas; Harold C. Simmons Comprehensive Cancer Center, UT Southwestern, Dallas, Texas. Electronic address: nicole.rich@utsouthwestern.edu. 2. Division of Digestive and Liver Diseases, Department of Internal Medicine, UT Southwestern, Dallas, Texas. 3. Harold C. Simmons Comprehensive Cancer Center, UT Southwestern, Dallas, Texas; Department of Surgery, UT Southwestern, Dallas, Texas. 4. Karsh Division of Gastroenterology and Hepatology, Comprehensive Transplant Center and Samuel Oschin Comprehensive Cancer Institute, Cedars Sinai Medical Center, Los Angeles, California. 5. Division of Digestive and Liver Diseases, Department of Internal Medicine, UT Southwestern, Dallas, Texas; Harold C. Simmons Comprehensive Cancer Center, UT Southwestern, Dallas, Texas. 6. Harold C. Simmons Comprehensive Cancer Center, UT Southwestern, Dallas, Texas; Department of Radiation Oncology, UT Southwestern, Dallas, Texas. 7. Division of Digestive and Liver Diseases, Department of Internal Medicine, UT Southwestern, Dallas, Texas; Harold C. Simmons Comprehensive Cancer Center, UT Southwestern, Dallas, Texas; Center for Human Nutrition, UT Southwestern, Dallas, Texas.
Abstract
BACKGROUND & AIMS: Cancer cachexia is a wasting syndrome associated with functional impairment and reduced survival that impacts up to 50% of patients with gastrointestinal cancers. However, data are limited on the prevalence and clinical significance of cachexia in patients with hepatocellular carcinoma (HCC). METHODS: We performed a retrospective cohort study of patients diagnosed with HCC at 2 United States health systems between 2008 and 2018. Patient weights were recorded 6 months prior to and at time of HCC diagnosis. Cachexia was defined as >5% weight loss (or >2% weight loss if body mass index <20 kg/m2), and precachexia was defined as 2% to 5% weight loss. We used multivariable logistic regression models to identify correlates of cachexia and multivariable Cox proportional hazard models to identify factors associated with overall survival. RESULTS: Of 604 patients with HCC, 201 (33.3%) had precachexia and 143 (23.7%) had cachexia at diagnosis, including 19.0%, 23.5%, 34.7%, and 34.0% of patients with Barcelona Clinic Liver Cancer stages 0/A, B, C, and D, respectively. Patients with cachexia were less likely to receive HCC treatment (odds ratio, 0.38; 95% confidence interval, 0.21-0.71) and had worse survival than those with precachexia or stable weight (11.3 vs 20.4 vs 23.5 months, respectively; P < .001). Cachexia remained independently associated with worse survival (hazard ratio, 1.43; 95% confidence interval, 1.11-1.84) after adjusting for age, sex, race, ethnicity, Child Pugh class, alpha-fetoprotein, Barcelona Clinic Liver Cancer stage, and HCC treatment. CONCLUSIONS: Nearly 1 in 4 patients with HCC present with cachexia, including many with compensated cirrhosis or early stage tumors. The presence of cancer-associated weight loss appears to be an early and independent predictor of worse outcomes in patients with HCC.
BACKGROUND & AIMS: Cancer cachexia is a wasting syndrome associated with functional impairment and reduced survival that impacts up to 50% of patients with gastrointestinal cancers. However, data are limited on the prevalence and clinical significance of cachexia in patients with hepatocellular carcinoma (HCC). METHODS: We performed a retrospective cohort study of patients diagnosed with HCC at 2 United States health systems between 2008 and 2018. Patient weights were recorded 6 months prior to and at time of HCC diagnosis. Cachexia was defined as >5% weight loss (or >2% weight loss if body mass index <20 kg/m2), and precachexia was defined as 2% to 5% weight loss. We used multivariable logistic regression models to identify correlates of cachexia and multivariable Cox proportional hazard models to identify factors associated with overall survival. RESULTS: Of 604 patients with HCC, 201 (33.3%) had precachexia and 143 (23.7%) had cachexia at diagnosis, including 19.0%, 23.5%, 34.7%, and 34.0% of patients with Barcelona Clinic Liver Cancer stages 0/A, B, C, and D, respectively. Patients with cachexia were less likely to receive HCC treatment (odds ratio, 0.38; 95% confidence interval, 0.21-0.71) and had worse survival than those with precachexia or stable weight (11.3 vs 20.4 vs 23.5 months, respectively; P < .001). Cachexia remained independently associated with worse survival (hazard ratio, 1.43; 95% confidence interval, 1.11-1.84) after adjusting for age, sex, race, ethnicity, Child Pugh class, alpha-fetoprotein, Barcelona Clinic Liver Cancer stage, and HCC treatment. CONCLUSIONS: Nearly 1 in 4 patients with HCC present with cachexia, including many with compensated cirrhosis or early stage tumors. The presence of cancer-associated weight loss appears to be an early and independent predictor of worse outcomes in patients with HCC.
Authors: Nicole E Rich; Caitlin Hester; Mobolaji Odewole; Caitlin C Murphy; Neehar D Parikh; Jorge A Marrero; Adam C Yopp; Amit G Singal Journal: Clin Gastroenterol Hepatol Date: 2018-05-31 Impact factor: 11.382
Authors: Kenneth Fearon; Florian Strasser; Stefan D Anker; Ingvar Bosaeus; Eduardo Bruera; Robin L Fainsinger; Aminah Jatoi; Charles Loprinzi; Neil MacDonald; Giovanni Mantovani; Mellar Davis; Maurizio Muscaritoli; Faith Ottery; Lukas Radbruch; Paula Ravasco; Declan Walsh; Andrew Wilcock; Stein Kaasa; Vickie E Baracos Journal: Lancet Oncol Date: 2011-02-04 Impact factor: 41.316
Authors: Jennifer C Lai; Robert S Rahimi; Elizabeth C Verna; Matthew R Kappus; Michael A Dunn; Mara McAdams-DeMarco; Christine E Haugen; Michael L Volk; Andres Duarte-Rojo; Daniel R Ganger; Jacqueline G O'Leary; Jennifer L Dodge; Daniela Ladner; Dorry L Segev Journal: Gastroenterology Date: 2019-01-19 Impact factor: 22.682
Authors: Nicole E Rich; Caitlin C Murphy; Adam C Yopp; Jasmin Tiro; Jorge A Marrero; Amit G Singal Journal: Aliment Pharmacol Ther Date: 2020-06-29 Impact factor: 9.524
Authors: Markus S Anker; Richard Holcomb; Maurizio Muscaritoli; Stephan von Haehling; Wilhelm Haverkamp; Aminah Jatoi; John E Morley; Florian Strasser; Ulf Landmesser; Andrew J S Coats; Stefan D Anker Journal: J Cachexia Sarcopenia Muscle Date: 2019-02 Impact factor: 12.910
Authors: Nicole E Rich; Aarthi Parvathaneni; Ahana Sen; Mobolaji Odewole; Ana Arroyo; Arjmand R Mufti; Thomas A Kerr; Lafaine Grant; Shannan R Tujios; Marlyn J Mayo; William M Lee; Ju Dong Yang; Takeshi Yokoo; Purva Gopal; Yujin Hoshida; Hao Zhu; Adam C Yopp; Jorge A Marrero; Amit G Singal Journal: Dig Dis Sci Date: 2021-05-03 Impact factor: 3.487